1. Home
  2. VMD vs CRDF Comparison

VMD vs CRDF Comparison

Compare VMD & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viemed Healthcare Inc.

VMD

Viemed Healthcare Inc.

HOLD

Current Price

$9.98

Market Cap

369.2M

Sector

N/A

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.52

Market Cap

114.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VMD
CRDF
Founded
2006
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
369.2M
114.2M
IPO Year
2018
2012

Fundamental Metrics

Financial Performance
Metric
VMD
CRDF
Price
$9.98
$1.52
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
208.5K
1.5M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
32.14
27.37
EPS
0.06
N/A
Revenue
$270,280,000.00
$365,993.00
Revenue This Year
$17.88
N/A
Revenue Next Year
$14.98
N/A
P/E Ratio
$164.00
N/A
Revenue Growth
20.52
49.61
52 Week Low
$5.93
$1.35
52 Week High
$10.18
$4.56

Technical Indicators

Market Signals
Indicator
VMD
CRDF
Relative Strength Index (RSI) 57.87 43.31
Support Level $9.22 N/A
Resistance Level $10.05 $1.76
Average True Range (ATR) 0.32 0.18
MACD 0.02 -0.03
Stochastic Oscillator 93.53 26.00

Price Performance

Historical Comparison
VMD
CRDF

About VMD Viemed Healthcare Inc.

Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: